Steven Cohen Janux Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $51 Billion
- Q3 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,710,200 shares of JANX stock, worth $50.1 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,710,200
Previous 2,143,900
20.23%
Holding current value
$50.1 Million
Previous $49.5 Million
15.6%
% of portfolio
0.08%
Previous 0.11%
Shares
6 transactions
Others Institutions Holding JANX
# of Institutions
182Shares Held
54.8MCall Options Held
598KPut Options Held
212K-
Ra Capital Management, L.P. Boston, MA11.2MShares$328 Million4.7% of portfolio
-
Janus Henderson Group PLC London, X04.7MShares$138 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$85.5 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$81.3 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$70.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.22B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...